SCM
APGE icon

Superstring Capital Management’s Apogee Therapeutics APGE Stock Holding History

Superstring Capital Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-36,928
Closed -$1.45M – 31
2024
Q2 		$1.45M Sell
36,928
-7,940
-18% -$385K 1.83% 16
2024
Q1 		$2.98M Buy
+44,868
New +$1.96M 1.97% 16

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Superstring Capital Management's APGE Position: Q3 2024 in Review

Superstring Capital Management sold out of Apogee Therapeutics (APGE) in Q3 2024, closing a stake of 36,928 shares — an estimated $1.45M sold.

Superstring Capital Management first reported a position in APGE in Q1 2024 and held it in 2 quarters. The position peaked at $2.98M in Q1 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q3 2024.

  • Superstring Capital Management reported no remaining Apogee Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Superstring Capital Management sold 36,928 Apogee Therapeutics shares in Q3 2024, an estimated $1.45M.
  • Superstring Capital Management first reported a position in Apogee Therapeutics in Q1 2024 and held it in 2 quarters.
  • Superstring Capital Management's Apogee Therapeutics position peaked at $2.98M in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2024.

Based on Superstring Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.